Table 1.
Patient demographics and disease characteristics at baseline
| Characteristic | All patients (N = 20) |
|---|---|
| Sex | |
| Female, n (%) | 11 (55) |
| Age, years | |
| Mean (SD) | 40.9 (8.95) |
| Median (range) | 39 (25–63) |
| Ethnicity, n (%) | |
| Caucasian | 18 (90) |
| Arab | 1 (5) |
| Hispanic | 1 (5) |
| Age at epilepsy onset, years* | |
| Mean (SD) | 16.3 (11.9) |
| Median (range) | 15 (0–47) |
| Aetiology, n (%) | |
| Focal cortical dysplasia | 5 (25) |
| Mesial temporal sclerosis syndrome | 5 (25) |
| Nonlesional focal | 5 (25) |
| GAD-epilepsy | 2 (10) |
| Cavernoma | 1 (5) |
| Congenital | 1 (5) |
| Tuberous sclerosis | 1 (5) |
| Frequency of seizures, n (%) | |
| Daily | 10 (50) |
| Weekly | 7 (35) |
| Monthly | 3 (15) |
| Epileptogenic focus | |
| Left temporal | 7 (35) |
| Bitemporal | 4 (20) |
| Left frontal | 4 (20) |
| Right temporal | 3 (15) |
| Right frontal | 1 (5) |
| Multifocal | 1 (5) |
| Mean cenobamate starting dose, mg (SD) | 12.5 (0.0) |
| Number of previous ASMs | |
| Mean (SD) | 10.2 (3.03) |
| Median (range) | 10 (3) |
| Number of concomitant ASMs, n (%) | |
| 1 | 0 (0) |
| 2 | 5 (25) |
| 3 | 10 (50) |
| ≥ 4 | 5 (25) |
| Mean (SD) | 3 (0.8) |
| Median (range) | 3 (2–5) |
| Prior epilepsy surgery, n (%) | 5 (25) |
ASMs antiseizure medications, GAD-epilepsy GAD65 antibody-associated autoimmune epilepsy, SD standard deviation
*N = 19